Technique and results of “higher-dose” infusion

Publisher Website
Google Scholar
Abstract
We experimented with thrombolytic technique in an attempt to maximize therapeutic outcome, selecting urokinase because of its proven safety and efficacy in clinical investigation. An initially “high-dose” regimen, starting at 4,000 U/min and decreasing to 1,000 U/min after restoration of antegrade blood flow, generally establishes lysis within 3–4 h—even after acute embolic or thrombolytic occlusion. It can also be used effectively and safely as a therapeutic trial. “High-dose” urokinase compares favorably with “low-dose” streptokinase and shows a lower incidence of bleeding and allergic complications.